Roche Pharma India partners with Entero Healthcare Solutions to improve access to nephrology medicines

Roche Products (India) Pvt. Ltd. has signed a distribution agreement with Entero Healthcare Solutions Pvt. Ltd. for promotion, marketing and distribution of its nephrology drugs - Mycophenolate Mofetil (Cellcept), Valganciclovir (Valcyte), Epoetin Beta (NeoRecormon), and Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in India

This partnership aims to address the unmet medical needs and broaden access to innovative medicines for patients across India

Roche Products (India) Pvt. Ltd. (Roche Pharma) and Entero Healthcare Solutions Pvt. Ltd. (Entero) today announced that the two companies have entered into an agreement to provide better access to innovative medicines for patients in India. Under this agreement, Entero will be responsible for promotion, marketing and distribution of Roche Pharma’s key nephrology drugs viz., Mycophenolate Mofetil (Cellcept), Valganciclovir (Valcyte), Epoetin Beta (NeoRecormon), and Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in India.

Roche Products (India) Pvt. Ltd. has been taking multiple steps to increase the reach of their innovations in India. The company is expanding its presence in different states in India by increasing its field force in a phased manner and investing in new talent in India over the next few months. The partnership deal, the discussions for which has been going on for the last few months, will help the company focus on these states and capabilities.Currently, the company has more than 2000 people working across states and through various partners in India.

“While we keep working towards creating and enhancing the healthcare ecosystem in India, we need to differentiate between our existing products that can reach the patients at a faster pace through a valued partnership like this, and the newer innovative drugs that we can focus on bringing into India in next few years.” said V. Simpson Emmanuel, General Manager, Roche Products (India) Pvt. Ltd.”At Roche Pharma India, we are focusing on strategic approaches to ensure robust access, better healthcare financing and overall enhanced healthcare ecosystem. A partnership in India for our Nephrology portfolio is one such important step in ensuring that we bring world-class medicines and healthcare solutions to our country through an esteemed partner like Entero Healthcare Solutions.We remain committed to transforming healthcare in India to become a benchmark for other emerging markets around the globe.”

Prabhat Agrawal, Co-founder and CEO, Entero Healthcare Solutions Pvt. Ltd. said, “We are delighted to enter this unique collaboration with Roche to be able to serve patient needs in the area of organ transplant and chronic kidney disease. There has been a significant rise in the number of patients with kidney related ailments and with Entero’s presence across major cities in India, we aspire to make these innovative set of medicines accessible to every patient.”

Entero, backed by OrbiMed (a leading global healthcare investment firm), is conceptualized to become the most preferred supply chain partner driven by integrated technology led solutions and scale advantages for all the stakeholders in the healthcare ecosystem.

Roche Products (India) Private Limited was incorporated in 1994 as a wholly owned subsidiary of the Roche Group, headquartered in Basel, Switzerland. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.

For more than 60 years, Roche has been committed to making a difference to the lives of people in India. Today, Roche is the leader in oncology treatment in India; apart from cancer, Roche’s has innovative medicines in other therapy areas too: transplantation, rheumatoid arthritis (RA), and chronic kidney disease (CKD)-related anaemia. Roche believes in making the latest and most innovative medicines accessible to patients in India in the fastest possible time.

Roche has been developing medicines with the goal to redefine treatment in oncology over the last 50 years. Today, Roche is investing more than ever in our effort to bring innovative treatment options that help a person’s own immune system fight cancer.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. This website is neither intended nor designed to record or report adverse event information. If you have a suspected side effect or problem to report regarding one of our products, visit us atOR please call the Roche India Safety Unit onor E-mail us at

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePersonalised HealthcareSolutionsRoche careersMediaPrivacy policyLegal statement